Naphazoline information

Naphazoline
Clinical data
Trade names	Clear Eyes, Cleari, Naphcon-A, Rohto
AHFS/Drugs.com	Monograph
Routes of; administration	Ophthalmic drug administration, nasal administration
ATC code	R01AA08 (WHO) S01GA01 (WHO);
Legal status
Legal status	In general: Over-the-counter (OTC);
Identifiers
	IUPAC name 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole;
CAS Number	835-31-4 ;
PubChem CID	4436;
IUPHAR/BPS	5509;
DrugBank	DB06711 ;
ChemSpider	4283 ;
UNII	H231GF11BV;
KEGG	D08253 ;
ChEMBL	ChEMBL761 ;
CompTox Dashboard (EPA)	DTXSID3048449 ;
ECHA InfoCard	100.011.492
Chemical and physical data
Formula	C14H14N2
Molar mass	210.280 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N\1=C(\NCC/1)Cc2cccc3c2cccc3;
	InChI InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16) ; Key:CNIIGCLFLJGOGP-UHFFFAOYSA-N ;
	(what is this?) (verify)

Naphazoline is a medicine used as a decongestant, and a vasoconstrictor added to eye drops to relieve red eye. It has a rapid action in reducing swelling when applied to mucous membranes. It is a sympathomimetic agent with marked alpha adrenergic activity that acts on alpha-receptors in the arterioles of the conjunctiva to produce constriction, resulting in decreased congestion.

It was patented in 1934 and came into medical use in 1942.^[1]

^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 552. ISBN 9783527607495.

[Fis2006-1] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 552. ISBN 9783527607495.

Naphazoline information

and 28 Related for: Naphazoline information

Naphazoline

Visine

Rhinitis medicamentosa

Miosis

Decongestant

ATC code R01

Rilmenidine

Topical decongestant

Antazoline

LSD

Levomethamphetamine

Nasal congestion

Norepinephrine

Propranolol

Salbutamol

Promethazine

Beta blocker

Xylazine

Tizanidine

Aripiprazole

Hydroxyzine

Trazodone

Tropicamide

Tyrosine

Mirabegron

Chlorpromazine

Phenylephrine

Clenbuterol